Novartis AG

See all company news

• (23.Jun.2022) Novartis Tafinlar + Mekinist Receives FDA Approval for First Tumor-Agnostic Indication for BRAF V600E Solid Tumors
• (22.Jun.2022) Novartis Receives European Commission Approval for Tabrecta for the Treatment of METex14 Skipping Advanced Non-Small Cell Lung Cancer
• (21.Jun.2022) Precision BioSciences Announces in Vivo Gene Editing Collaboration With Novartis to Develop Potentially Curative Treatment for Disorders Including Sickle Cell Disease
• (16.Jun.2022) PerkinElmer and Novartis Collaborate to Address the Unmet Need of Sickle Cell Disease in Sub-Saharan Africa
• (16.Jun.2022) Pliant Therapeutics Announces Advancement of Integrin Target in Fibrosis Under Strategic Collaboration
• (09.Jun.2022) BridgeBio Pharma to Present Phase 2b Data and Pivotal Phase 3 Study Design of Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1) at the Endocrine Society (ENDO) 2022 Annual Conference
• (08.Jun.2022) Novartis Pro Portal Reimagines Knowledge Exchange in Patient Care, With Seamless Collaboration Between the Pharmaceutical Industry and Physicians
• (08.Jun.2022) Health Canada Approves (Pr)Tabrecta: Targeted Cancer Therapy for Locally Advanced Unresectable or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harbouring Mesenchymal-Epithelial Transition (MET) Exon 14 Skipping Alterations
• (07.Jun.2022) Samsung Biologics Inks $81m Deal with Novartis
• (05.Jun.2022) Bihar to Host Clinical Trial on Revolutionary Tablet for Kala-Azar
• (31.May.2022) Sandoz Announces New Global 'Act4Biosimilars' Initiative, to Improve Patient Access and Increase Adoption by at Least 30% in 30+ Countries by 2030
• (27.May.2022) FDA Approves Novartis Kymriah CAR-T Cell Therapy for Adult Patients With Relapsed or Refractory Follicular Lymphoma
• (26.May.2022) Laekna Therapeutics Announces Dosing of First Patients in the U.S. And China in Phase Ib/Iii Study of Afuresertib in Combination With Fulvestrant in HR+/HER2- Breast Cancer
• (24.May.2022) International Process Plants Announces Purchase of World-Class Grimsby, UK API Pharmaceutical Manufacturing Site From Novartis
• (18.May.2022) Anji Pharma Completes Patient Enrollment in Phase 2 Study of Pradigastat in Functional Constipation
• (16.May.2022) CG Oncology Presents Additional Phase 2 Data With CG0070 in Combination With KEYTRUDA (Pembrolizumab) in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin
• (16.May.2022) Lek Receives a Special Award on the 15th Anniversary of the Family Friendly Company Certificate
• (12.May.2022) Sandoz Launches First Generic Pirfenidone in US for Patients With Idiopathic Pulmonary Fibrosis, Growing Its Respiratory Portfolio
• (05.May.2022) Societal CDMO Signs Three-Year Manufacturing and Supply Agreement With InfectoPharm for Ritalin LA in Europe
• (05.May.2022) Abelacimab: First Factor XI Inhibitor to Enroll Patients in a Phase 3 Clinical Trial
• (05.May.2022) Novartis Divested EU Rights of Ritalin LA Capsules to InfectoPharm
• (04.May.2022) Juniper Biologics Signs Exclusive License Agreement With Helsinn for Infigratinib (INN) for the Emerging Markets
• (04.May.2022) New Novartis Data Demonstrate Only Kisqali Offers More Life in the First-Line Setting for Postmenopausal HR+/HER2- Advanced Breast Cancer Patients
• (04.May.2022) EC Approves Novartis' Kymriah for Advanced Blood Cancer
• (03.May.2022) Vera Therapeutics Selected to Present Interim Phase 2 Data for MAU868 to Treat BK Virus in Kidney Transplant Patients as Oral Late-Breaker at the American Transplant Congress 2022
• (27.Apr.2022) Global Phase 3 Trial of BeiGene's PD-1 Inhibitor, Tislelizumab, in Combination With Chemotherapy Meets Primary Endpoint in First-Line Advanced Esophageal Squamous Cell Carcinoma
• (26.Apr.2022) Pharming Receives Agreement of Paediatric Investigation Plan and Promising Innovative Medicine Designation for Leniolisib From UK MHRA
• (26.Apr.2022) Novartis Delivers Solid Sales And Profit Growth. Strong Performance Of In-market Brands Supports Confidence In Mid-term Growth Outlook
• (25.Apr.2022) Ontario and Quebec Become the First Provinces to List Kesimpta (Ofatumumab) for the Treatment of Adults With Relapsing Remitting Multiple Sclerosis (RRMS)
• (25.Apr.2022) Novartis UK Launches Local Charity Partnerships to Support Social Mobility Pledges
• (22.Apr.2022) Incyte Announces Positive CHMP Opinion for Capmatinib (Tabrecta) for the Treatment of METex14 Advanced Non-Small Cell Lung Cancer
• (19.Apr.2022) Aptabio, 'Treatment Effect of Parkinson's Disease Through Oxidative Stress Control'
• (15.Apr.2022) China NMPA Approves Tislelizumab for Patients With Second-Line Esophageal Squamous Cell Carcinoma
• (14.Apr.2022) Sandoz Launches Generic Brimonidine Tartrate/Timolol Maleate Eyedrop in US for Patients with Ocular Hypertension, Expanding Leading Ophthalmic Portfolio
• (13.Apr.2022) CG Oncology Presents Interim Phase 2 Data With CG0070 in Combination With KEYTRUDA (Pembrolizumab) in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin
• (08.Apr.2022) BeiGene to Present Clinical Results and Biomarker Data on Tislelizumab in Solid Tumors at the AACR Annual Meeting 2022
• (08.Apr.2022) Lek Once Again Awarded for Good Practice in Intergenerational Cooperation
• (06.Apr.2022) FDA Approves Novartis Vijoice (Alpelisib) as First and Only Treatment for Select Patients With PIK3CA-Related Overgrowth Spectrum (PROS)
• (06.Apr.2022) BeiGene Announces European Medicines Agency Acceptance of Marketing Authorization Applications for Tislelizumab for the Treatment of Patients With ESCC and NSCLC
• (05.Apr.2022) Novartis Expands Zolgensma Manufacturing Capacity with Approval of Multi-Product North Carolina Facility
• (05.Apr.2022) Novartis Presents New Four-Year Data on Efficacy and Safety of Kesimpta (Ofatumumab) in People Living with Relapsing Multiple Sclerosis
• (04.Apr.2022) Novartis Restructures Organisation to Support Growth and Innovation
• (01.Apr.2022) Pharming Announces Positive Data From Phase II/III Leniolisib Trial Presented at Clinical Immunology Society 2022 Annual Meeting
• (31.Mar.2022) Novartis announces European Commission approval of Beovu® for people living with diabetic macular edema
• (29.Mar.2022) Novartis Will Include PYLARIFY (Piflufolastat F18) in Their Clinical Trials for Pluvicto (Lutetium Lu 177 Vipivotide Tetraxetan) for the Selection of Patients with Prostate Cancer
• (28.Mar.2022) New Peer-reviewed Research Shows No Increased Risk Of Serious Covid-19 Infections In Kesimpta (Ofatumumab)-treated Adults With Multiple Sclerosis
• (25.Mar.2022) ITM Provides n.c.a. Lutetium-177 as Long-Term Supplier for Recently Approved Novel Radiotherapeutic in Metastatic Prostate Cancer
• (25.Mar.2022) Incyte Announces Positive CHMP Opinion for Ruxolitinib (Jakavi) for the Treatment of Acute and Chronic Graft-Versus-Host Disease
• (25.Mar.2022) Novartis Receives Positive CHMP Opinion for Kymriah CAR-T Cell Therapy for Adult Patients With Relapsed or Refractory Follicular Lymphoma in Europe
• (24.Mar.2022) Novartis Slovenia Has Some of the Best HR Practices in the Country
• (23.Mar.2022) Novartis Pluvicto Approved by FDA as First Targeted Radioligand Therapy for Treatment of Progressive, PSMA Positive Metastatic Castration-Resistant Prostate Cancer
• (21.Mar.2022) Vera Therapeutics to Host BK Virus Webinar Featuring Stanley C. Jordan, M.D., World-Renowned Transplant Nephrologist and Pioneering Kidney Transplant Researcher
• (18.Mar.2022) Immutep Announces Second Japanese Patent Grant for Lag-3 Antagonist Antibody Lag525
• (14.Mar.2022) IDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreements for Evaluation of Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma and Additional cMET-Driven Tumors
• (14.Mar.2022) Independent Audits Confirm Lek's Quality When It Comes to Health, Safety, and Environment
• (14.Mar.2022) Novartis Data Again Demonstrate Age-Appropriate Development When Zolgensma is Used Presymptomatically, and Post-Hoc Data Reveal SMA Type 1 Patients Could Speak, Swallow and Maintain Airway Protection
• (14.Mar.2022) Sandoz Targets Growth Opportunities in Respiratory and Complex Generics Through Acquisition of Respiratory Device Company Coalesce
• (10.Mar.2022) Novartis Signs Initial Agreement with Carisma Therapeutics for the Manufacturing of HER 2 Targeted CAR-M Cell Therapy
• (09.Mar.2022) Voyager Therapeutics Announces License Option Agreement With Novartis for Target-Specific Access to Next-Generation TRACER AAV Capsids for Gene Therapy Programs
• (09.Mar.2022) NEJM Publication of Novartis Kisqali Data Shows Longest Median Overall Survival Ever Reported in HR+/HER2- Advanced Breast Cancer
• (04.Mar.2022) Costly Orphan Drug Lutathera Becomes Reimbursable
• (04.Mar.2022) Novartis Shareholders Approve All Resolutions Proposed by the Board of Directors at the Annual General Meeting
• (03.Mar.2022) Helsinn Group and BridgeBio Pharma Announce Update to Strategic Collaboration to Develop, Manufacture and Commercialize Infigratinib in Oncology Indications in the U.S
• (02.Mar.2022) Novartis Peer-Reviewed Safety and Tolerability Data Further Strengthens Kesimpta's (Ofatumumab) Favorable Benefit-Risk Profile in Patients with Relapsing Multiple Sclerosis
• (01.Mar.2022) Sterling Expands Global API Manufacturing Capabilities with Acquisition of Novartis Facility in Ringaskiddy, Ireland
• (25.Feb.2022) Novartis Femara Tablets 2.5 Mg Received Additional Approval for Regulatory Ovarian Stimulation in Assisted Reproductive Technology
• (24.Feb.2022) Valeo Pharma Obtains Public Reimbursement for Enerzair Breezhaler and Atectura Breezhaler in Ontario, Manitoba and New Brunswick
• (18.Feb.2022) Sandoz Launches Generic Oncology Treatment in Europe
• (18.Feb.2022) Gyroscope Therapeutics Acquisition is Complete
• (16.Feb.2022) Cambrian Biopharma Announces Licensing Agreement to Develop Selective mTOR Inhibitors
• (10.Feb.2022) Emergency Use Authorization Request for Ensovibep Submitted to the US Food and Drug Administration for the Treatment of COVID-19
• (08.Feb.2022) Leqvio Therapy to Lower Cholesterol Approved by FDA, IVX Health Now Accepting New Leqvio Patients
• (04.Feb.2022) Novartis in Slovenia is Celebrating a Year of Breakthrough Innovations and Strengthening Its Position as an Attractive Investment Location
• (02.Feb.2022) Pharming Announces Positive Results of Phase II/III Pivotal Clinical Study of Leniolisib for the Treatment of Activated PI3K Delta Syndrome
• (02.Feb.2022) Novartis Delivers Mid Single Digit Sales Growth, Margin Expansion and Advancement of Robust Pipeline in 2021
• (27.Jan.2022) 1st RWE Data Comes Out Confirming Efficacy of Zolgensma in Korean SMA Patients
• (20.Jan.2022) Novartis in Slovenia Once Again Impresses with Its HR Excellence and Wins the "Top Employer" Certificate for the Second Time
• (20.Jan.2022) New England Journal of Medicine. Researchers from CNIO and Hospital 12 De Octubre Take Part in Two International Trials to Expand the Indications of CAR-T Cell Immunotherapy
• (18.Jan.2022) Molecular Partners Finalizes License Agreement with Novartis for Ensovibep for Covid-19
• (14.Jan.2022) $421,000 Cancer Drug Kymriah Becomes Eligible for Reimbursement
• (11.Jan.2022) Sandoz and Aequus Agree to 1-Year Extension on Vistitan in Canada
• (11.Jan.2022) Helsinn and Xediton Sign Exclusive License and Distribution Agreement for TRUSELTIQ (Infigratinib) in Canada
• (10.Jan.2022) Novartis and Molecular Partners Report Positive Topline Data From Phase 2 Study for Ensovibep (MP0420), a DARPin Antiviral Therapeutic for COVID-19
• (09.Jan.2022) Laekna Therapeutics and Innovent Biologics Obtain IND Approval for Combination Therapy in Patients With Specific Types of Solid Tumors Who Have Been Refractory to Treatment With PD-1/PD-L1 Inhibitors
• (06.Jan.2022) Pharming Receives Positive EMA Decision on Paediatric Investigation Plan (PIP) for Leniolisib in Europe
• (06.Jan.2022) Alnylam Announces Collaboration With Novartis to Explore Targeted Therapy to Restore Liver Function
• (05.Jan.2022) Covis Enters Promotion and Distribution Agreement for Two Respiratory Medicines, Seebri Breezhaler and Ultibro Breezhaler, in Canada
• (05.Jan.2022) Amneal Acquires Saol Therapeutics' Baclofen Franchise
• (04.Jan.2022) Novartis Announces U.S. Court of Appeals for the Federal Circuit (CAFC) Upholds Validity of Gilenya (Fingolimod) Dosage Regimen Patent
• (04.Jan.2022) Sage Bionetworks and PPACMAN Release Psorcast App to Support Patients with Psoriatic Disease and Health Researchers
• (03.Jan.2022) Towards More Effective Tendon Repair with a Multi-Functional Biomaterial
• (28.Dec.2021) Branaplam on FDA's Fast Track; Phase 2 Trial Now Enrolling
• (22.Dec.2021) Novartis to Acquire Gyroscope Therapeutics, Adding a One-Time Gene Therapy That Could Transform Care for Geographic Atrophy, a Leading Cause of Blindness
• (22.Dec.2021) FDA Approves Novartis Leqvio (Inclisiran), First-in-Class siRNA to Lower Cholesterol and Keep It Low With Two Doses a Year
• (22.Dec.2021) Alnylam Comments on FDA Approval of Leqvio, the First siRNA (RNAi Therapeutic) Approved to Reduce LDL-C
• (22.Dec.2021) Novartis Cosentyx Receives FDA Approval for the Treatment of Children and Adolescents With Enthesitis-Related Arthritis and Psoriatic Arthritis
• (21.Dec.2021) Helsinn Group Announces European Medicines Agency's (EMA) Acceptance for Review of the Marketing Authorization Application (MAA) for Infigratinib for Patients with Cholangiocarcinoma with Fibroblast Growth Factor Receptor 2 Fusions or Rearrangements
• (21.Dec.2021) LianBio Announces Infigratinib Approved Under Special Named Patient Program for the Treatment of Cholangiocarcinoma in the Pilot Zone of Hainan Province in China
• (20.Dec.2021) Novartis Provides an Update on Phase III Ligelizumab (QGE031) Studies in Chronic Spontaneous Urticaria (CSU)
• (20.Dec.2021) Harrow Health Acquires U.S. Commercial Rights to Four Branded Eye Drops
• (20.Dec.2021) Novartis Strengthens Immunotherapy Pipeline With Option, Collaboration and License Agreement With BeiGene for TIGIT Inhibitor Ociperlimab
• (20.Dec.2021) CG Oncology Announces First Patient Dosed in Japan in Phase 3 Monotherapy Study of CG0070 in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin
• (17.Dec.2021) Beovu (Brolucizumab Injection) Now Publicly Reimbursed in Ontario and New Brunswick for the Treatment of Neovascular (Wet) Age-Related Macular Degeneration
• (17.Dec.2021) Vera Therapeutics Announces Acquisition of Monoclonal Antibody From Pfizer to Treat BK Virus in Transplant Patients
• (16.Dec.2021) Kura Oncology Doses First Patient in Phase 1/2 Clinical Trial of Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma
• (15.Dec.2021) Valeo Pharma Obtains Public Reimbursement for Enerzair Breezhaler and Atectura Breezhaler in Quebec and Nova Scotia
• (14.Dec.2021) Molecular Partners Announces Collaboration With Novartis to Develop DARPin-Conjugated Radioligand Therapeutic Candidates for Oncology
• (14.Dec.2021) CAR T-Cell Therapy Found Equivalent to Standard of Care as Second-Line Treatment for Aggressive Non-Hodgkin Lymphoma
• (14.Dec.2021) APONTIS PHARMA and Midas Pharma Announce Development Partnership to Launch Single Pill with Pan-European Intellectual Property Rights
• (13.Dec.2021) Novartis Announces T-Charge, Next-Generation CAR-T Platform With First-in-Human Data at ASH 2021
• (13.Dec.2021) Update on Novartis Agreement
• (13.Dec.2021) Oxford Biomedica Updates and Extends Commercial Supply Agreement for Manufacture of Lentiviral Vectors
• (11.Dec.2021) Novartis Kymriah Demonstrates Strong Responses in High-Risk Patients With Relapsed or Refractory Follicular Lymphoma in Extended Study Follow-Up
• (11.Dec.2021) Novartis Scemblix Demonstrates Sustained Response Rate in 48-Week Follow-Up in Patients With Chronic Myeloid Leukemia
• (10.Dec.2021) Novartis Data Highlight Efficacy of Piqray in HR+/HER2- Metastatic Breast Cancer With a PIK3CA Driver Mutation Immediately Post-Cdk4/6i
• (09.Dec.2021) Acromegaly Treatment's Supply Suspended as Novartis Hands Over Sales Rights
• (08.Dec.2021) New Kisqali Data Shows Consistent Overall Survival Benefit Across Genomic and Clinical Subtypes of Interest in HR+/HER2- Metastatic Breast Cancer
• (07.Dec.2021) IDEAYA Reports Clinical Data From Phase 2 Expansion Dose of Darovasertib and Crizotinib Synthetic Lethal Combination in Heavily Pre-Treated Metastatic Uveal Melanoma
• (07.Dec.2021) Atrial Fibrillation Clinical Trial With Novel Dual Activity Factor XI Agent Completes Enrollment
• (06.Dec.2021) Molecular Partners Presents Results from a Phase 2A Trial of Ensovibep in 12 Covid-19 Patients at ESWI 2021
• (06.Dec.2021) Roche Completed the Repurchase of Roche Shares from Novartis
• (02.Dec.2021) UCB Announces Global Partnership to Bring Disease-Modifying Therapies to People Living With Parkinson's Disease
• (01.Dec.2021) IFM Therapeutics Announces Extension of Collaboration Agreement for cGAS-STING Subsidiary, IFM Due
• (30.Nov.2021) Secura Bio Announces U.S. Withdrawal of FARYDAK (Panobinostat) NDA
• (25.Nov.2021) Novartis Launches Virtual Innovation Hub to Accelerate Digital Health Solutions in Sub-Saharan Africa
• (24.Nov.2021) Novartis' MET Inhibitor Tabrecta Wins Permit for Lung Cancer in Korea
• (19.Nov.2021) Phase 2 Trial of CMK389 Recruiting Adults with Pulmonary Sarcoidosis
• (16.Nov.2021) Molecular Partners Provides Update From ACTIV-3 Global Clinical Study of Ensovibep in Patients Hospitalized With COVID-19
• (15.Nov.2021) Kedalion Therapeutics Secures Series B Funding and Announces Signing of Option to Acquire Agreement
• (13.Nov.2021) CG Oncology Presents Preliminary Phase 2 Data With CG0070 in Combination With KEYTRUDA (Pembrolizumab) in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin
• (11.Nov.2021) Real-World Study Proves Zolgensma's Safety, Efficacy in Pediatric SMA Patients
• (11.Nov.2021) Novartis Licenses Patented Drug-Discovery Platform Technologies From Housey Pharma
• (09.Nov.2021) Preclinical Data Supporting Therapeutic Potential of Surface Oncology's Lead Clinical Programs, SRF617 and SRF388, Presented at the Society for Immunotherapy of Cancer 2021 Annual Meeting
• (08.Nov.2021) First and Only Randomized, Double-Blind, Head-To-Head Study Comparing Aimovig (Erenumab-Aooe), an Anti-CGRP Pathway Therapy, to Topiramate Published in Cephalalgia
• (05.Nov.2021) Roche and Novartis Part Ways With Share Purchase
• (04.Nov.2021) XOMA Earns $35 Million Milestone Payment as Anti-TGFβ Antibody Enters Phase 3 Clinical Study in Metastatic Pancreatic Cancer
• (04.Nov.2021) Novartis Iptacopan Meets Primary Endpoints in Phase II Study in Rare Kidney Disease C3 Glomerulopathy (C3G)
• (03.Nov.2021) Valeo Pharma Obtains Public Reimbursement for Enerzair Breezhaler and Atectura Breezhaler in Alberta
• (03.Nov.2021) Novartis in Slovenia is Joining Movember Thus Raising Awareness of Prostate Cancer
• (02.Nov.2021) Dunad Therapeutics Enters Strategic Collaboration With Novartis to Develop Next-Generation Oral Targeted Protein Degrader Therapies
• (29.Oct.2021) FDA Approves Novartis Scemblix (Asciminib), With Novel Mechanism of Action for the Treatment of Chronic Myeloid Leukemia
• (28.Oct.2021) Court Raises Korean Drugmakers' Hands in Patent Dispute Over Novartis
• (27.Oct.2021) Novartis Receives Priority Review By US FDA And Filing Acceptance By Ema For Kymriah To Treat Patients With Relapsed Or Refractory Follicular Lymphoma
• (26.Oct.2021) Novartis Delivers Solid Q3 Results, With Strong Growth In Innovative Medicines. Announces Strategic Review Of Sandoz
• (25.Oct.2021) Novartis Top-Line Results for CANOPY-1 Phase III Study Support Further Evaluation of Canakinumab in Lung Cancer
• (21.Oct.2021) Novartis Signs New Initial Agreement With Biontech To Support Fill And Finish Of The mRNA Pfizer-BioNTech COVID-19 Vaccine
• (20.Oct.2021) Molecular Partners Present Data Demonstrating Successful Inhibition of Covid19 Viral Variants with Ensovibep at the 2021 ISIRV-WHO Conference
• (15.Oct.2021) Novartis Applauds Quebec, the First Province to List Zolgensma for the Treatment of Pediatric Patients With Spinal Muscular Atrophy (SMA)
• (14.Oct.2021) Novartis's Certican Proves Immunosuppressive Effects in Asian Kidney Transplant Patients
• (14.Oct.2021) Kesimpta (Ofatumumab) Data At ECTRIMS Highlights Preservation Of IgG Levels And Safety Experience Over Extended Exposure (~3.5 Years) In People Living With Relapsing Multiple Sclerosis
• (13.Oct.2021) Novartis and the Pan-Canadian Pharmaceutical Alliance (pCPA) Complete Negotiations for Zolgensma for the Treatment of Pediatric Patients With Spinal Muscular Atrophy (SMA)
• (13.Oct.2021) Novartis Slovenia Receives The Silver National Award For Innovation
• (13.Oct.2021) Novartis Announces FDA And EMA Filing Acceptances Of Beovu For Patients With Diabetic Macular Edema
• (11.Oct.2021) Sandoz Completes Acquisition of GSK's Cephalosporin Business
• (05.Oct.2021) The First Treatment for Sickle Cell Disease in Over 20 Years, Novartis' Adakveo (Crizanlizumab) Receives NICE Recommendation for Preventing Recurrent Vaso-Occlusive Crises
• (05.Oct.2021) Innodem Neurosciences Signs a Strategic Partnership With Novartis Pharmaceuticals Canada Inc
• (05.Oct.2021) Novartis Pharmaceuticals Canada Inc. Announces Digital Innovation Partnership in Multiple Sclerosis With Innodem Neurosciences
• (04.Oct.2021) Boston Pharmaceuticals Doses First Patient in Phase 2a Clinical Trial of BOS-580 for NASH
• (01.Oct.2021) Sandoz Resolves Legacy Federal Government Civil Investigation in the U.S. Regarding Generic Drugs
• (30.Sep.2021) Novartis Data Show Rapid And Effective Disease Activity Control With Remibrutinib (LOU064) In Patients With Chronic Spontaneous Urticaria
• (29.Sep.2021) Novartis and Medicines for Malaria Venture Report Positive Results for Phase 2b Study of Novel Ganaplacide/Lumefantrine Combination in Children With Malaria
• (29.Sep.2021) New Data Reinforce Efficacy And Convenience Of Novartis Cosentyx (Secukinumab) 300 Mg Autoinjector In Adults With Psoriasis
• (29.Sep.2021) Helsinn Group and BridgeBio Pharma's Affiliate QED Therapeutics Announce Health Canada Conditional Approval of TRUSELTIQ (Infigratinib) for Patients with Cholangiocarcinoma
• (28.Sep.2021) FDA Grants Priority Review for Investigational Targeted Radioligand Therapy 177Lu-Psma-617 for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
• (27.Sep.2021) Kisqali Extends Survival by 1 Year in Advanced Breast Cancer
• (22.Sep.2021) Theragnostics Announces Licensing Agreement for Development and Commercialization of One-Step PET Radiopharmaceuticals
• (22.Sep.2021) Credence MedSystems Secures $39.9 Million Financing to Enable Scaling of Innovative Drug Delivery and Connected Health Systems
• (22.Sep.2021) CG Oncology and Roche to Collaborate on Clinical Trial of Oncolytic Immunotherapy CG0070 as Part of Novel Combination for Various Solid Tumor Indications
• (22.Sep.2021) Eckert & Ziegler's GalliaPharm, Exclusively Distributed by Jubilant Radiopharma, Approved for Use with NETSPOT in Canada
• (21.Sep.2021) Novartis Acquires Arctos Medical, Expanding Optogenetics Portfolio to Bring Gene Therapies to Patients With Severe Vision Loss
• (21.Sep.2021) Lek Receives the 2021 Energy Efficient Company Award
• (19.Sep.2021) Novartis Presents New Kisqali Data Showing Longest Median Overall Survival Ever Reported in HR+/HER2- Advanced Breast Cancer
• (17.Sep.2021) Novartis Announces Findings From a Real-World Study of Alpelisib Demonstrating Clinical Benefit in People With PIK3CA-Related Overgrowth Spectrum (PROS)
• (16.Sep.2021) Laekna Therapeutics Reported Positive Results in Two Clinical Studies for the Treatment of Various Stages of Prostate Cancer at the ESMO Congress
• (16.Sep.2021) Novartis Reports Positive Health-Related Quality of Life Data for 177Lu-Psma-617 Radioligand Therapy in Patients With Advanced Prostate Cancer at ESMO 2021
• (16.Sep.2021) Allarity Therapeutics Presents Dovitinib Survival Data from DRP Screened RCC Patients at ESMO 2021 Virtual Congress
• (13.Sep.2021) BeiGene Announces U.S. FDA Acceptance of Biologics License Application for Tislelizumab in Esophageal Squamous Cell Carcinoma
• (10.Sep.2021) The National Institute of Chemistry Awarded Lek for Its Involvement in Research Work
• (09.Sep.2021) Regulators OKs Novartis' Inherited Retinal Dystrophy Treatment
• (09.Sep.2021) CG Oncology Announces Clinical Trial Collaboration With Bristol Myers Squibb to Evaluate Oncolytic Immunotherapy CG0070 in Combination With OPDIVO (Nivolumab) in Metastatic Urothelial Cancer
• (07.Sep.2021) Reimbursement Uncertain for Piqray Targeting PIK3CA Mutation in Breast Cancer
• (07.Sep.2021) Adlai Nortye Announces First Patient Dosed in Phase Ia Clinical Trial of AN2025 and AN0025 in Combination With Atezolizumab for Advanced Solid Tumors
• (06.Sep.2021) Novartis Presents New Paradigm for Treating Progressive, Metastatic Breast Cancer
• (06.Sep.2021) TB Alliance and Lupin Announce Commercial Partnership for New Therapy for Highly Drug-Resistant TB
• (03.Sep.2021) Novartis Announces Discontinuation of CIRRUS-1 Study of CFZ533 (Iscalimab) in Kidney Transplant Patients
• (03.Sep.2021) Novartis Presents New Findings At ERS Reinforcing The Efficacy Of Enerzair Breezhaler, Highlighting Its Digital Companion, As Well As Showcasing Commitment To Low Carbon Footprint Asthma Solutions
• (02.Sep.2021) UK's NICE Recommends Anti-Cholesterol Leqvio for High-Risk Patients
• (01.Sep.2021) World-first Agreement Between Novartis And The NHS Enables Broad And Rapid Access To First-in-class Cholesterol-lowering Medicine Leqvio
• (31.Aug.2021) Launch of Therapeutic Radiopharmaceutical Product, Lutathera Injection Targeting Neuroendocrine Tumors in Japan
• (30.Aug.2021) Novartis Korea Releases Study on Aggressive Lymphoma Patients
• (30.Aug.2021) Novartis Leqvio (Inclisiran) Analyses Show Effective and Sustained LDL-C Reduction in Two Sub-Populations of Patients with ASCVD
• (26.Aug.2021) Laekna Therapeutics Receives IND Approvals in China and US for Phase Ib/Iii Global Multi-Center Clinical Study of Afuresertib in Combination With Fulvestrant for Patients With HR+/HER2- Breast Cancer
• (25.Aug.2021) Ocumension Acquires All the Equity Interests in Two Ophthalmic Products Mainland China, Further Enhancing Its Pipeline Strength
• (25.Aug.2021) BridgeBio Pharma and LianBio Announce First Patient Treated in Phase 2a Trial of Infigratinib in Patients With Gastric Cancer and Other Advanced Solid Tumors
• (24.Aug.2021) Novartis Provides Update on BELINDA Study Investigating Kymriah as Second-Line Treatment in Aggressive B-Cell Non-Hodgkin Lymphoma
• (23.Aug.2021) NICE Recommends Novartis' Rydapt for Advanced SM Treatment
• (17.Aug.2021) Novartis Announces Positive Results from Phase III Trials of Beovu in Diabetic Macular Edema, Including Dosing Intervals up to 16 Weeks
• (17.Aug.2021) Novartis Secures New Approval in China for Cosentyx (Secukinumab) in Pediatric Psoriasis
• (12.Aug.2021) Bluejay: Combining HBV Therapies to Reach A Functional Cure
• (06.Aug.2021) Survival Benefit of Adding Noxopharm's Veyonda to Novartis' LuPSMA Confirmed in Pre-Clinical Study
• (03.Aug.2021) Yuyu Pharma Signs Exclusive Distribution Agreement With Novartis Korea for Domestic Distribution Rights in Korea for Lamisil, Lescol XL and Tegretol
• (03.Aug.2021) Novartis Announces Lift of Partial Clinical Trial Hold and Plans to Initiate a New, Pivotal Phase 3 Study of Intrathecal OAV-101 in Older Patients With SMA
• (03.Aug.2021) Lotus Confirms Patent Challenge for Generic Rydapt
• (03.Aug.2021) Novartis Announces Lift of Partial Clinical Trial Hold and Plans to Initiate a New, Pivotal Phase 3 Study of Intrathecal OAV-101 in Older Patients with SMA
• (02.Aug.2021) Novartis' Psoriatic Arthritis Drug to Get Expanded Reimbursement
• (02.Aug.2021) Lp(a) HORIZON Achieves 50% Enrollment in Trial to Assess the Safety and Efficacy of Pelacarsen in Reducing Recurrent Cardiovascular Events
• (28.Jul.2021) U.S. Food and Drug Administration Has Granted Orphan Drug Designation to XOMA's Licensed Anti-TGFβ Asset NIS793
• (28.Jul.2021) Children's Hospital of Philadelphia Researchers Develop "Dimmer Switch" to Help Control Gene Therapy
• (26.Jul.2021) Tunable Switch via Oral Small Molecule Controls Gene Therapy Expression Levels
• (22.Jul.2021) Plexxikon Wins Patent Infringement Case Against Novartis
• (21.Jul.2021) Novartis Delivered Strong Q2 Performance, Driven By Momentum Of Key Growth Brands. FY 2021 Guidance Unchanged.
• (21.Jul.2021) Community Update: Status of Study of Branaplam/LMI070 in SMA
• (20.Jul.2021) Novartis Pledges 10-Year Commitment With Morehouse School of Medicine, 26 Historically Black Colleges, Universities, Medical Schools and Other Leading Organizations to Co-Create Effective, Measurable Solutions for Health Equity
• (18.Jul.2021) Ninety Day Survival Outcomes in COVID-19 ARDS Trial of Remestemcel-L Presented at ISCT Meeting on Advances in Cell & Gene Therapies for Lung Diseases
• (16.Jul.2021) Sandoz Launches First Generic High Dose Intravenous Iron, Ferumoxytol Injection, to Treat US Patients With Iron Deficiency Anemia
• (15.Jul.2021) Mesoblast Presents Respiratory Function Results of COVID-19 ARDS Trial at Pulmonary Disease Conference
• (14.Jul.2021) Novartis Announces NEJM Publication of Positive Phase III REACH3 Data for Jakavi in Chronic GvHD
• (14.Jul.2021) Codexis Announces Completion of CodeEvolver License Technology Transfer with Global Pharmaceutical Leader
• (09.Jul.2021) Novartis Korea to Continue Discussing Reimbursement Plan for SMA Drug Zolgensma
• (08.Jul.2021) Molecular Partners Reports Continued Progress of Ensovibep Global Clinical Program; Positive in Vitro Data Demonstrating Maintained Inhibition of Delta and All Other Known Variants of Concern of Sars-cov-2
• (06.Jul.2021) Kura Oncology Announces Clinical Collaboration to Evaluate Tipifarnib in Combination With Alpelisib in Head and Neck Squamous Cell Carcinoma
• (29.Jun.2021) Cancer Targeted Technology Receives Milestone Payment for Development of Diagnostic PET Imaging Agent for Prostate Cancer
• (28.Jun.2021) Novartis appoints Rob Kowalski as Chief People & Organization Officer